

**PRESS RELEASE**

12 September 2023 11:01:00 CEST

## **Senzime has submitted application for cross-trading at OTCQX in the US**

**Senzime, an industry leader in algorithm-based patient monitoring solutions announces the submission of an application for cross-trading of the Senzime share on the OTCQX trading platform. Upon approval, Senzime's shares will in parallel to its current Nasdaq Main Market listing, be traded with a US ticker symbol and a share price in USD.**

OTCQX is a trading platform in the United States operated by the OTC Markets Group, as an alternative to listing on Nasdaq New York and NYSE. Cross-trading on OTCQX helps satisfy an increasing interest from US investors and increase accessibility to the US capital market. Upon approval, Senzime's shares will be traded with a US ticker symbol and a share price in USD, during US market hours.

"Around 15 percent of the shares in Senzime are held by US investors, and the majority of our revenues are generated from the US market. As a result, we want to make it easier for US investors to trade in the Senzime share", comments Philip Siberg, CEO of Senzime AB.

**For further information, please contact:**

---

Philip Siberg, CEO of Senzime AB

Phone: +46 (0) 707 90 67 34, e-mail: [philip.siberg@senzime.com](mailto:philip.siberg@senzime.com)

Slavoljub Grujicic, CFO

Phone: +46 (0) 76 306 60 11, e-mail: [slavoljub.grujicic@senzime.com](mailto:slavoljub.grujicic@senzime.com)

### **About Senzime**

---

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at [senzime.com](https://senzime.com).

## Attachments

---

Senzime has submitted application for cross-trading at OTCQX in the US